Free Trial

Weiss Ratings Reiterates Sell (D-) Rating for NAMI (NASDAQ:NAMI)

NAMI logo with Business Services background

Key Points

  • Weiss Ratings has reiterated a "sell (D-)" rating for NAMI (NASDAQ:NAMI), indicating ongoing concerns over the stock's performance.
  • NAMI's stock price opened at $0.98, significantly below its one-year high of $7.75, with current moving averages at $1.05 for 50 days and $1.74 for 200 days.
  • XTX Topco Ltd acquired a stake in NAMI, purchasing 26,778 shares valued at approximately $75,000, reflecting some interest from hedge funds despite the negative rating.
  • MarketBeat previews top five stocks to own in November.

NAMI (NASDAQ:NAMI - Get Free Report)'s stock had its "sell (d-)" rating reiterated by research analysts at Weiss Ratings in a research report issued on Wednesday,Weiss Ratings reports.

NAMI Trading Up 4.8%

Shares of NAMI stock opened at $0.98 on Wednesday. The stock has a 50 day moving average price of $1.05 and a 200-day moving average price of $1.74. NAMI has a one year low of $0.84 and a one year high of $7.75.

Hedge Funds Weigh In On NAMI

A hedge fund recently bought a new stake in NAMI stock. XTX Topco Ltd acquired a new stake in shares of NAMI Corp. (NASDAQ:NAMI - Free Report) in the first quarter, according to the company in its most recent 13F filing with the SEC. The fund acquired 26,778 shares of the company's stock, valued at approximately $75,000.

About NAMI

(Get Free Report)

Jinxin Technology Holding Co engages in the provision of digital content services. The company was founded in August 2015 and is headquartered in Shanghai, China.

Featured Stories

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in NAMI Right Now?

Before you consider NAMI, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and NAMI wasn't on the list.

While NAMI currently has a Sell rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

The Next 7 Blockbuster Stocks for Growth Investors Cover

Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.

Get This Free Report
Like this article? Share it with a colleague.